GenEdit is a South San Francisco, California-based startup developing alternative methods of delivering gene-based and CRISPR-based medicines.
Subscribe to see Genedit’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Genedit is a healthcare company headquartered in United States. It has raised at least $108M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $60M in February 2026. Xcout tracks 2 named people at Genedit, including Kun-woo Lee (CEO).
At least $108M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $60M | 12 named | |
| Series A1 | $24M | 12 named | |
| — | $24M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Genedit's closest competitors — see the full list of competitors and alternatives →
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Spot Biosystems is a gene therapy company pioneering a novel non-viral extracellular delivery approach. Headquartered in Palo Alto, California, the company launched with significant financing to advance its therapeutic pipeline.
GEMMABio is a privately held therapeutics company founded in 2024 in Philadelphia, Pennsylvania, dedicated to developing novel gene therapies for rare diseases.
Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California. The firm engages in developing next-generation cancer immunotherapies and vaccines to fight various forms of cancer and infectious diseases.
CureGenetics is a biotechnology company headquartered in Suzhou, China, focused on the development of gene and cutting-edge medical therapies.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.